Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.
Diabetic Foot Ulcer · Peripheral Arterial Disease · Wound; Foot
Primary: Transcutaneous Oxygen Pressure (TcPO2) — 50.96 mmHg
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
N/A N=53 MIRODERM H2H DFU Study
Diabetic Foot Ulcer
Primary: Percentage of Participants — 57.89 Percentage of participants with healed u
N/A N=51 Ultrasound Assisted Wound Debridement (UAW) Versus Standard Wound Treatment in Complicated Diabetic Foot Ulcers (DFU)
Diabetic Foot Ulcer
Primary: Change From Baseline Neo-angiogenesis (Microvessel Density) at 6 Weeks — 2.82; 1.77 score on a scale — p=<0.01
N/A N=23 Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers
Foot Ulcer, Diabetic
Primary: Tissue Oxygenation as Measured by Hyperspectral Imaging — 63.58; 61.91; 76.33; 77.55 percent concentration of oxyhemoglobin
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients
N/A N=8 ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
Diabetes
Primary: Number of Day Until 50% Healing of Leg Ulcer — 55; 30 Days
N/A N=20 Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology
Diabetic Foot Ulcer
Primary: Adherence to Use of SmartMat — 6.4 number of foot scans/week
N/A N=28 High Purity Type I Collagen Based Skin Substitute Vs Dehydrated Human Amnion/Chorion Membrane in Treatment of DFUs
Diabetic Foot Ulcer (DFU)
Primary: Percentage Wound Area Epithelialization From Week 1 Through 4 — 93.62; 77.71 percentage wound area epithelialization
Phase 1 N=11 Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment
Diabetes Type I · Diabetes Type II
Primary: Percentage of Wound Area Reduction Compared to Baseline — 87 percentage of wound closure
N/A N=39 Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth — 2.05; 3.33 mm^3
Phase 3 N=48 Beta Adrenergic Antagonist for the Healing of Chronic DFU
Chronic Diabetic Foot Ulcers · Diabetic Neuropathic Ulcers · Non Healing Wound
Primary: Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period — 8; 7 Participants
N/A N=160 Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer
Diabetic Foot Ulcer
Primary: Demographic Characteristics: Weight (Mean) — 73.7; 78.3 kg
N/A N=24 Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers
Diabetic Foot Ulcer · Diabetes Mellitus, Type 2
Primary: Glycated Hemoglobin (HbA1c) at 12-week Session — 8.0; 7.0 percentage of HbA1c — p=.26
N/A N=24 Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Percentage of Wound Area Reduction — 83.9; 71.3 Percentage of Wound Area Reduction
Phase 4 N=82 Study of Oasis Ultra in Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Percentage of Wounds Closed — 54; 32 percentage of wounds closed
Phase 4 N=17 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Wound Appearance — 19; 19; 16.9; 14.5 units on a scale
N/A N=148 Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
Diabetic Foot Ulcer · Ulcer Foot · Diabetic Foot
Primary: Complete Wound Healing — 32; 16; 32; 16 Participants — p=0.007
N/A N=20 CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers
Diabetic Foot Ulcer
Primary: Bacterial Load — -99.9; -50.0 Percent change from baseline
Phase 4 N=106 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
Chronic Foot Ulcers
Primary: Full Epithelialization of the Wound — 16; 8 participants — p=<0.05
Phase 2 N=30 Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Diabetic Foot Infections
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)…
N/A N=31 Diabetic Foot Ulcer Study on Topical Interventions
Diabetic Foot
Primary: Number of Participants With Complete Healing of Ulcer During the Observation Period — 9; 5; 4 participants
Phase 3 N=206 Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups…
N/A N=30 Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
Diabetic Foot Ulcer
Primary: Percentage of Participants With Wound Closed — 75 percentage of participants
N/A N=21 Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU When Using Fast Gelling Dressing as Intended.
Diabetic Foot Ulcers
Primary: Change in Peri-wound Skin — 8 participants
Phase 4 N=102 Use of Santyl in Diabetic Foot Ulcers
Diabetic Foot · Foot Ulcer, Diabetic
Primary: Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment. — 57.6; 41.3 percentage of change from baseline (cm2)
N/A N=24 TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended
Diabetic Foot Ulcers
Primary: Changes in Signs and Symptoms of Local Infection — 2; 1; 0 Participants